PLK1 inhibitors exhibit relatively consistent hematologic toxicities, particularly neutropenia, thrombocytopenia, and anemia, which are the most common dose-limiting toxicities; neutropenia can occur in approximately 25%–40% of patients, highlighting the importance of close monitoring of hematology parameters in clinical application (Ahn et al., 2024; Jimeno et al., 2008; Pujade-Lauraine et al., 2016; de Braud et al., 2015). Here, PLK1 is linked to neutropenia.